David Qian, Ph.D.
- click here
Dr. Qian’s laboratory studies the molecular and cellular mechanism of chemotherapy stress response and resistance and the epigenetics of hypoxia. The lab is investigating ways to target prostate cancer cells and angiogenesis with HDAC inhibitors.
"Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer,"
"Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism,"
"HIF1Î± protein stability is increased by acetylation at lysine 709,"
"Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours,"
"A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma,"